Evaluation of the timing of the booster injection after a primary vaccination against hepatitis A

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 2, 1997, Pages 172-175

  Fujiyama, Shigetoshi ^a   Odoh, Koichi ^b   Tanaka, Motohiko ^a   Kuramoto, Izumi ^a   Tomita, Kimio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Anti HAV titres; Hepatitis A; Hepatitis A vaccine; Hepatitis A virus; Immune serum globulin

Indexed keywords

HEPATITIS A VACCINE; IMMUNOGLOBULIN;

ADULT; ARTICLE; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION; VOLUNTEER;

EID: 0031037297     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00402.x     Document Type: Article

References (19)

1. Fujiyama S, Odoh K, Kuramoto I, Mizuno K, Tsurusaki R, Sato T. Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination. J. Hepatol. 1994; 21: 641-5.
2. Kumashiro R, Sata M, Setoyama H, Tanikawa K. Acute hepatitis A superimposed on liver cirrhosis: A report of four cases. Acta Hepatol. Jpn. 1985; 26: 1400-6 (in Japanese).
3. Kumashiro R, Sata M, Suzuki H, Tanikawa K. Clinical study of acute hepatitis type A in patients older than fifty years. Acta Hepatol. Jpn. 1988; 29: 457-62 (in Japanese).
4. Lemon SM. Inactivated hepatitis A virus vaccines. Hepatology 1992; 15: 1194-7.
5. Fujiyama S, Iino S, Odoh K et al. Time course of hepatitis A virus antibody titer after active and passive immunization. Hepatology 1992; 15: 983-8.
6. Moritsugu Y, Totsuka A. Hepatitis A vaccine: Current status of development. In: Fukai K, ed., Virus Vaccine in Asian Countries. Tokyo: University of Tokyo Press, 1986; 193-201.
7. Iino S, Fujiyama S, Horiuchi K et al. Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1992; 10: 323-8.
8. Iino S. Phase II clinical study of DCK-171 (hepatitis A vaccine). Clin. Report 1992; 26: 5325-36 (in Japanese).
9. Iino S, Tanikawa K, Miyake K et al. Phase III clinical study of DCK-171 (hepatitis A vaccine). Clin. Report 1993; 27: 237-44 (in Japanese).
10. Kuramoto I, Fujiyama S, Odoh K, Mizuno K, Sato T. Long-term follow-up of antibody titers after hepatitis A vaccination. Int. Hepatol. Commun. 1993; 1: 194-9.
11. Sjogren MH, Eckels KH, Binn LN et al. Safety and immunogenicity of an inactivated hepatitis A vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988; 94-6.
12. Fleming B, Heinricy U, Pfisterer M. Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet 1989; i: 1039-41.
13. Wiedermann G, Ambrosch F, Kollaritsch H et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990; 8: 581-4.
14. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: An overview. J. Hepatol. 1993; 18 (Suppl. 2): S51-5.
15. André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings. Vaccine 1992; 10: S160-8.
16. Berger R, Just M. Vaccination against hepatitis A: Control 3 years after the first vaccination. Vaccine 1992; 10: 295 (Letter).
17. Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. j. Med. 1992; 327: 453-7.
18. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
19. Prikazsky V, Oleár V, Cernoch A et al. Interruption of an outbreak of hepatitis A in two villages by vaccination. J. Med. Virol. 1994; 44: 457-9.